Search Results
Oct 17, 2025, 09:03 ET SEATTLE REIGN FC ANNOUNCES MULTI-YEAR UPPER-BACK KIT PARTNERSHIP WITH PAULA'S CHOICE SKINCARE
its official debut on the Reign FC kit Reign FC also introduces the Lu Barnes Award, presented by Paula's Choice Skincare, to annually honor a Reign FC player who exemplifies integrity, leadership and excellence - with captain
More news about: Paula's Choice
Oct 17, 2025, 04:35 ET Shanghai-London Screen Industry Forum Returns for Third Edition, Strengthening Sino-British Creative Ties and Showcasing Global Storytelling
Special Projects at Pinewood Group; Jason ZHANG, Founder and Producer of Stellar Pictures; FU Wenjie, Executive Vice President of Xixi Pictures; and Roy LU, General Manager of Linmon International. The agenda also featured a fireside chat with acclaimed Chinese actor ZHANG Luyi, offering a personal perspective
More news about: Phoenix TV
Oct 17, 2025, 04:00 ET Shanghai-London Screen Industry Forum Returns for Third Edition, Strengthening Sino-British Creative Ties and Showcasing Global Storytelling
Special Projects at Pinewood Group; Jason ZHANG, Founder and Producer of Stellar Pictures; FU Wenjie, Executive Vice President of Xixi Pictures; and Roy LU, General Manager of Linmon International. The agenda also featured a fireside chat with acclaimed Chinese actor ZHANG Luyi, offering a personal perspective
More news about: Phoenix TV
Oct 16, 2025, 08:50 ET Gstarsoft presenta una nueva línea de productos y estrategia global
húngaro de software BIM, y la creación de una nueva filial, Gstar Hawk3D, para impulsar el desarrollo internacional de productos BIM. Como compartió Lu Xiang, consejero delegado de Gstarsoft, la compañía también estableció una estrecha colaboración con Zixel Technology para desarrollar conjuntamente
More news about: Gstarsoft Co., Ltd.
Oct 16, 2025, 00:15 ET HARMONi-6 Phase III Study of Ivonescimab Accepted by The Lancet and Selected for ESMO 2025 LBA Presentation
Congress. The HARMONi-6 trial result has been selected as a Late-Breaking Abstract (LBA) for the 2025 ESMO Congress. Professor Lu Shun, Director of the Oncology Department at Shanghai Chest Hospital, presented the study's findings at the Presidential Symposium. The results of this
More news about: Akeso, Inc.
Oct 15, 2025, 18:11 ET Gstarsoft stellt neue Produktpalette und globale Strategie vor und setzt damit neue Maßstäbe für Industriesoftware
BIM-Software, und die Gründung einer neuen Tochtergesellschaft, Gstar Hawk3D, um die internationale Entwicklung von BIM-Produkten voranzutreiben. Wie Lu Xiang, CEO von Gstarsoft, mitteilte, ist das Unternehmen auch eine intensive Zusammenarbeit mit Zixel Technology eingegangen, um gemeinsam 3D-CAD-Lösungen
More news about: Gstarsoft Co., Ltd.
Oct 15, 2025, 18:10 ET Gstarsoft dévoile sa nouvelle gamme de produits et sa stratégie mondiale, établissant ainsi une nouvelle référence en matière de logiciels industriels
logiciels BIM, et en créant une nouvelle filiale, Gstar Hawk3D, pour piloter le développement de produits BIM à l'échelle internationale. Comme l'a indiqué Lu Xiang, PDG de Gstarsoft, l'entreprise a également entamé une collaboration étroite avec Zixel Technology pour développer conjointement des solutions
More news about: Gstarsoft Co., Ltd.
Oct 15, 2025, 17:31 ET Gastrointestinal Neuroendocrine Tumors Market Set to Surge by 2034 Amidst Advancements in Treatment Options | DelveInsight
such as LUTATHERA (¹⁷⁷Lu-DOTATATE), have broadened treatment options for somatostatin receptor–positive tumors by providing targeted therapy with demonstrated improvements in progression-free survival. Emerging radiopharmaceuticals, like ITM-11 (n.c.a. ¹⁷⁷Lu-edotreotide), show promise for enhanced
More news about: DelveInsight Business Research, LLP
Oct 15, 2025, 11:00 ET Fullcast Announces the Acquisition of Copy.ai
"Fullcast shares our belief that the future of sales and marketing is AI-native, data-driven and outcome-driven," said Chris Lu, CTO and co-founder of Copy.ai. "By joining forces, we're combining Copy.ai's generative content engine with Fullcast's RevOps platform to create something
More news about: Fullcast
Oct 15, 2025, 10:57 ET AtWork Stands Out as the Only Staffing Franchise to Grow Sales on the Franchise Times Top 400 List
https://www.atwork.com/. Media Contact: Lu DumasTidehouse Agency(954) [email protected]
More news about: AtWork
Oct 15, 2025, 09:00 ET Helix GenoSphere™ Launches MASH-Enriched Cohort of Over 17,000 Linked Clinico-Genomic Records to Accelerate Drug Discovery and Development
GenoSphereTM platform, researchers and drug developers can identify key insights needed to create more effective and targeted treatments," said James Lu, M.D., Ph.D., CEO of Helix. "Fueled by the largest precision health network in North America, Helix is in a unique position to help accelerate discoveries
More news about: Helix
Oct 15, 2025, 04:50 ET PAObank and OneConnect Financial Technology Join HKMA's Second Cohort of GenA.I. Sandbox to Enhance Deepfake Fraud Detection
Limited PAO Bank Limited ("PAObank"), a wholly-owned subsidiary of Lufax Holding Ltd ("Lufax") (SEHK: 6623; NYSE: LU) and a member of Ping An Insurance (Group) Company of China, Ltd. ("Ping An") (SEHK:2318; SSE:601318), is committed to fostering financial inclusion and
More news about: Ping An Insurance (Group) Company of China, Ltd.
Oct 15, 2025, 02:57 ET 台湾紅茶が和紅茶に挑戦？苗栗獅潭紅茶、日本市場に上陸して消費者の認知度を獲得
[email protected] Mio +886 907-152-286Claire Peng +886 910-213-168Allen Lu +886 925-603-032
More news about: Sunny Bank
Oct 15, 2025, 02:00 ET Gstarsoft Unveils New Product Lineup and Global Strategy, Setting a New Benchmark for Industrial Software
acquiring CadLine, a Hungarian BIM software developer, and forming a new subsidiary, Gstar Hawk3D, to drive international BIM product development. As Lu Xiang, CEO of Gstarsoft, shared, the company also entered a deep collaboration with Zixel Technology to co-develop next-generation 3D CAD solutions.
More news about: Gstarsoft Co., Ltd.
Oct 14, 2025, 12:00 ET Five Award-Winning Immigrant Filmmakers Featured at Hawai'i International Film Festival
Waialae Avenue | 203M LUCKY LU, written and directed by Lloyd Lee Choi (b. Canada), premiered at the 2025 Cannes Film Festival. Choi's feature film expertly depicts the struggles and hopes of immigrants in America through the journey of Lu, a food delivery driver whose bike is stolen
More news about: The Vilcek Foundation
Oct 14, 2025, 08:30 ET Kyoto University Engineering Ph.D. Team Achieves Technology Transformation in Chengdu; LivingPhoenix's Biomimetic Collagen Rated "International Leading-Edge"
featured Dr. Zhang Xinling of Beijing Hospital as the first author and Dr. Li Kexin of The University of Tokyo as a co-first author. Contributors included Lu Nan, Dr. Takafumi Takebayashi, Dr. Zhou Boyu, and Xie Hongbin. The related peer-reviewed paper was published in the SCI Q1 journal Frontiers in Bioengineering
More news about: LivingPhoenix
Oct 14, 2025, 08:00 ET 20 MW of Solar and BESS Power Purchase Agreements Secured by PowerBank with the New York State Division of Military and Naval Affairs (DMNA)
resiliency, climate, and economic savings goals. Construction is expected to start by the end of the 2025 calendar year. Dr. Richard Lu, President & CEO of PowerBank commented: "This is another exciting development project for PowerBank. With over a decade of experience as a trusted
More news about: PowerBank Corporation
Oct 13, 2025, 12:10 ET Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
receptor inhibitor enzalutamide (Xtandi®) and 177Lu-PSMA-617 radiotherapy, the active agent in Pluvicto®, durable tumor control and potent efficacy in prostate cancer models resistant to both enzalutamide and 177Lu-PSMA-617. In addition, ATNM-400 has demonstrated synergy with enzalutamide.
More news about: Actinium Pharmaceuticals, Inc.
Oct 13, 2025, 08:30 ET Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat
receptor inhibitor enzalutamide (Xtandi®) and 177Lu-PSMA-617 radiotherapy, the active agent in Pluvicto®, durable tumor control and potent efficacy in prostate cancer models resistant to both enzalutamide and 177Lu-PSMA-617. In addition, ATNM-400 has demonstrated synergy with enzalutamide.
More news about: Actinium Pharmaceuticals, Inc.
Oct 11, 2025, 08:45 ET C-Ray Therapeutics (Chengdu) Co., Ltd Congratulates Partner Biokin Pharmaceutical on NMPA IND Approval of First Proprietary ARC Drug [177Lu]-BL-ARC001
Pharmaceutical, on receiving implied approval from the National Medical Products Administration (NMPA) for the clinical trial application of [177Lu]-BL-ARC001 Injection, the company's first radiopharmaceutical and a Class 1 innovative biologic. This milestone approval
More news about: C Ray Therapeutics
Oct 09, 2025, 09:00 ET Infor Unveils Built-for-Industry AI Agents to Revolutionize Operational Workflows
significantly enhance ERP functionality—delivering faster access to information, quicker issue resolution, and improved customer satisfaction," said Shen Lu, CIO, Gellert Global. "By automating repetitive tasks, these agents enable employees to focus on higher-value work that drives organization growth and
More news about: Infor
Oct 09, 2025, 06:04 ET Beijing Review: Rivers, Rice and Revolution
the delegation admired masterpieces ranging from traditional opera characters to modern creative designs. In hands-on sessions, senior craftsman Zhou Lu from Huishan Clay Figurine Factory taught reporters how to paint clay pandas. Huishan clay figurines have a history of more than
More news about: Beijing Review
Oct 07, 2025, 10:01 ET Momentum Introduces the New Vida E+
momentum-biking.com and follow @momentumbiking. Media Contacts:JJ Lu, Momentum [email protected] 886 4 2460 9099
More news about: Momentum
Oct 07, 2025, 03:00 ET Blue Earth Therapeutics Presents Modelling Data Supporting Early Dose Intensification of Lutetium (177Lu) rhPSMA-10.1 Injection in mCRPC
results demonstrating that front-loaded dosing of its radiohybrid lutetium labelled, PSMA targeted, investigational radioligand therapy Lutetium (177Lu) rhPSMA-10.1 Injection may increase cumulative tumour absorbed radiation dose without a proportional increase in normal organ exposure or total
More news about: Blue Earth Therapeutics
Oct 07, 2025, 03:00 ET Blue Earth Therapeutics Presents Modelling Data Supporting Early Dose Intensification of Lutetium (177Lu) rhPSMA-10.1 Injection in mCRPC
results demonstrating that front-loaded dosing of its radiohybrid lutetium labelled, PSMA targeted, investigational radioligand therapy Lutetium (177Lu) rhPSMA-10.1 Injection may increase cumulative tumour absorbed radiation dose without a proportional increase in normal organ exposure or total
More news about: Blue Earth Therapeutics